香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 新銳醫藥國際控股有限公司 主席兼執行董事 二 零 二 四 年 年 報－ 補充資料 茲 提 述 新 銳 醫 藥 國 際 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 年 度 的 年 報（「二零二四年年報」）。本 公 告 所 用 詞 彙 與 二 零 二 四 年 年 報 所 界 定 者 具 有 相 同 涵 義。 二 零 二 四 年 年 報 披 露，本 集 團 按 公 平 值 計 入 損 益 列 賬 之 金 融 資 產 包 括 於 嵊 州 新 銳 萬 馬 之 投 資，其 公 平 值 佔 本 集 團 於 二 零 二 四 年 十 二 月 三 十 一 日 的 經 審 核 總資產約5.9%。本 公 司 謹 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 第 2 頁 共 10 頁 v 1.1.1 公司名稱: 新銳醫藥國際控股有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06108 | 說明 | 新銳醫藥 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | HKD | | 0.01 HKD | | 150,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 15,000,000,000 | HKD | | ...

[Company Information](index=2&type=section&id=公司資料) This section provides New Ray Medicine International Holding Limited's basic corporate information, including registration, stock code, and contact details [Board of Directors and Committees](index=3&type=section&id=董事會及委員會) This section lists New Ray Medicine International Holding Limited's board members and their committee memberships - The Board of Directors comprises three executive directors (Ms. Wang Qiuqin, Mr. Chu Xueping, Ms. Zhou Wan) and three independent non-executive directors (Mr. Leung Chi Kin, Ms. Li Qianming, Mr. Sze Lai Shan)[3](index=3&type=chunk) - The Audit Committee, Remuneration Committee, and Nomination Committee are all chaired by independent non-executive directors[3](index=3&type=chunk) [Basic Company Information](index=3&type=section&id=基本公司信息) This section provides New Ray Medicine International Holding Limited's basic corporate information, including registration, stock code, and contact Basic Company Information | Metric | Details | | :--- | :--- | | Stock Code | 6108 | | Registered Office | Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda | | Headquarters | 37th Floor, B–C, Dikai International Center, No. 19 Dangui Road, Hangzhou, People's Republic of China | | Principal Place of Business in Hong Kong | Room 911B, 9th Floor, Tower 1, The Gateway, 30 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong | | Website | www.newraymedicine.com | [Financial Highlights](index=4&type=section&id=財務概要) This section provides a concise overview of the Group's key financial performance and position for the period [Financial Highlights for the Six Months Ended June 30, 2025](index=4&type=section&id=截至二零二五年六月三十日止六個月財務概要) For the six months ended June 30, 2025, revenue grew by 167.4%, but net loss attributable to owners increased by 82.3% Financial Performance for the Six Months Ended June 30, 2025 | Metric | 2025 (HK$'000) | 2024 (HK$'000) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 44,701 | 16,718 | +167.4% | | Net Loss Attributable to Owners of the Company | (7,454) | (4,088) | +82.3% | | Interim Dividend | Nil | Nil | - | - As of June 30, 2025, the Group's gearing ratio remained **zero**, consistent with December 31, 2024, indicating no bank or other borrowings[5](index=5&type=chunk) [Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=5&type=section&id=簡明綜合損益及其他全面收益表) This section presents the Group's financial performance, including revenue, cost of sales, gross profit, and net loss for the period [Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=5&type=section&id=簡明綜合損益及其他全面收益表) For the six months ended June 30, 2025, revenue increased, but gross profit declined due to higher cost of sales, resulting in a net loss Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (For the Six Months Ended June 30) | Metric | 2025 (HK$'000) | 2024 (HK$'000) | | :--- | :--- | :--- | | Revenue | 44,701 | 16,718 | | Cost of sales | (41,065) | (10,492) | | Gross profit | 3,636 | 6,226 | | Loss before tax | (7,454) | (4,083) | | Loss for the period attributable to owners of the Company | (7,454) | (4,088) | | Loss per share (HK cents) | (0.45) | (0.24) | - Total other comprehensive expenses for the period amounted to **HK$46,577 thousand**, primarily impacted by fair value losses on equity instruments at fair value through other comprehensive income[7](index=7&type=chunk) [Condensed Consolidated Statement of Financial Position](index=6&type=section&id=簡明綜合財務狀況表) This section outlines the Group's assets, liabilities, and equity, providing a snapshot of its financial health at period-end [Condensed Consolidated Statement of Financial Position](index=6&type=section&id=簡明綜合財務狀況表) As of June 30, 2025, total assets less current liabilities decreased, mainly due to a reduction in equity instruments at fair value through OCI Condensed Consolidated Statement of Financial Position (As at June 30, 2025) | Metric | June 30, 2025 (HK$'000) | December 31, 2024 (HK$'000) | | :--- | :--- | :--- | | Total non-current assets | 127,790 | 177,315 | | Total current assets | 319,477 | 327,920 | | Total current liabilities | 16,698 | 27,312 | | Net current assets | 302,779 | 300,608 | | Total assets less current liabilities | 430,569 | 477,923 | | Equity attributable to owners of the Company | 424,379 | 470,956 | - Equity instruments at fair value through other comprehensive income decreased from **HK$102,367 thousand** as of December 31, 2024, to **HK$53,428 thousand** as of June 30, 2025[8](index=8&type=chunk) [Condensed Consolidated Statement of Changes in Equity](index=7&type=section&id=簡明綜合權益變動表) This section details the changes in the Group's equity attributable to owners, including profit/loss and other comprehensive income [Statement of Changes in Equity](index=7&type=section&id=權益變動表) Equity attributable to owners decreased, primarily due to loss for the period and other comprehensive expenses Changes in Equity Attributable to Owners of the Company (For the Six Months Ended June 30) | Metric | June 30, 2025 (HK$'000) | June 30, 2024 (HK$'000) | | :--- | :--- | :--- | | Equity at beginning of period | 470,956 | 483,723 | | Loss for the period | (7,454) | (4,088) | | Other comprehensive expenses for the period | (39,123) | (10,964) | | Equity at end of period | 424,379 | 468,671 | - Equity instruments at fair value through other comprehensive income (non-recycling reserve) recorded an expense of **HK$46,300 thousand** in the first half of 2025, a key factor in the equity reduction[9](index=9&type=chunk) [Notes](index=7&type=section&id=附註) This section explains the nature and accounting treatment of various reserves within the condensed consolidated statement of changes in equity - Contributed surplus primarily represents the share conversion difference arising from the Group's 2013 reorganization, net of dividends declared in 2014[10](index=10&type=chunk) - Chinese subsidiaries are required to set aside a statutory surplus reserve fund at **10% of net profit after tax**, which can be used to offset losses or for capitalization issues[10](index=10&type=chunk) - Accumulated gains or losses from the revaluation of equity instruments at fair value through other comprehensive income are recognized in other comprehensive income and transferred to retained profits upon disposal[10](index=10&type=chunk) [Condensed Consolidated Statement of Cash Flows](index=8&type=section&id=簡明綜合現金流量表) This section presents the Group's cash flows from operating, investing, and financing activities for the period [Condensed Consolidated Statement of Cash Flows](index=8&type=section&id=簡明綜合現金流量表) For the six months ended June 30, 2025, net cash outflow from operating activities led to a net decrease in cash and cash equivalents Condensed Consolidated Statement of Cash Flows (For the Six Months Ended June 30) | Metric | 2025 (HK$'000) | 2024 (HK$'000) | | :--- | :--- | :--- | | Net cash outflow from operating activities | (16,838) | (192) | | Net cash inflow (outflow) from investing activities | 3,570 | (14,820) | | Net cash outflow from financing activities | (1,367) | (719) | | Net decrease in cash and cash equivalents | (14,635) | (15,731) | | Cash and cash equivalents at end of period | 54,153 | 87,478 | - Cash and cash equivalents at the end of the period amounted to **HK$54,153 thousand**, a decrease from **HK$64,255 thousand** at the beginning of the period[12](index=12&type=chunk) [Notes to the Condensed Consolidated Financial Statements](index=9&type=section&id=簡明綜合財務報表附註) This section provides detailed explanations and disclosures supporting the condensed consolidated financial statements [1. General Information](index=9&type=section&id=1.%20一般資料) New Ray Medicine International Holding Limited, an investment holding company, primarily engages in pharmaceutical distribution and marketing services in China - The Company is an investment holding company, with its principal operating subsidiaries engaged in the distribution and trading of pharmaceutical and related products and providing marketing and promotion services in China[14](index=14&type=chunk) - The Company's functional currency is Renminbi, but the condensed consolidated financial statements are presented in Hong Kong Dollars[14](index=14&type=chunk) [2. Basis of Preparation](index=9&type=section&id=2.%20編製基準) The condensed consolidated financial statements are prepared under HKAS 34 and Listing Rules, and should be read with the annual financial statements - The condensed consolidated financial statements are prepared in accordance with Hong Kong Accounting Standard 34 'Interim Financial Reporting' and the applicable disclosure requirements of Appendix D2 to the Listing Rules[15](index=15&type=chunk) - The condensed consolidated financial statements do not include all information and disclosures required in annual financial statements and should be read in conjunction with the Group's annual financial statements for the year ended December 31, 2024[15](index=15&type=chunk) [3. Significant Accounting Policies Information](index=10&type=section&id=3.%20重大會計政策資料) The condensed consolidated financial statements are prepared on a historical cost basis, with certain financial instruments measured at fair value - The condensed consolidated financial statements are prepared on a historical cost basis, except for certain financial instruments measured at fair value[16](index=16&type=chunk) - During the period, amendments to Hong Kong Financial Reporting Standards issued by the HKICPA were first adopted, including HKAS 21 (Amendment) 'Lack of Exchangeability'[17](index=17&type=chunk) - The application of the amendments to HKFRSs had no significant impact on the Group's financial position and performance and/or disclosures for the current and prior periods[17](index=17&type=chunk) [4. Revenue and Segment Information](index=10&type=section&id=4.%20收益及分部資料) The Group's revenue primarily derives from pharmaceutical product distribution and marketing services in China, with all revenue originating from China - The Group is principally engaged in the distribution and trading of pharmaceutical products and providing marketing and promotion services in China[18](index=18&type=chunk) Revenue by Business Segment (For the Six Months Ended June 30) | Business Segment | 2025 (HK$'000) | 2024 (HK$'000) | | :--- | :--- | :--- | | Distribution and trading of pharmaceutical and related products | 43,058 | 12,116 | | Provision of marketing and promotion services | 1,643 | 4,602 | | **Total** | **44,701** | **16,718** | - All of the Group's revenue from external customers is derived from China[25](index=25&type=chunk) [5. Other Income, Gains and Losses](index=12&type=section&id=5.%20其他收入、收益及虧損) For the six months ended June 30, 2025, the Group recorded a net other loss, primarily due to reduced bank interest and dividend income Other Income, Gains and Losses (For the Six Months Ended June 30) | Item | 2025 (HK$'000) | 2024 (HK$'000) | | :--- | :--- | :--- | | Bank interest income | 396 | 1,315 | | Dividend income | 1 | 420 | | Net exchange loss | (1,107) | (1,184) | | **Total** | **(709)** | **735** | - Bank interest income significantly decreased from **HK$1,315 thousand** in 2024 to **HK$396 thousand** in 2025[26](index=26&type=chunk) [6. Income Tax Expense](index=12&type=section&id=6.%20所得稅開支) The Group reported zero income tax expense for the six months ended June 30, 2025, as no taxable profits were generated Income Tax Expense (For the Six Months Ended June 30) | Item | 2025 (HK$'000) | 2024 (HK$'000) | | :--- | :--- | :--- | | Current tax: PRC Enterprise Income Tax | – | – | | Deferred tax | – | 5 | | **Total tax expense for the period** | **–** | **5** | - The tax rate for the Company's PRC subsidiaries is **25%**, but no tax provision was made as the Group had no taxable profits in either period[27](index=27&type=chunk) [Loss for the Period is Arrived at After Charging](index=13&type=section&id=期內虧損於扣除下列各項後達致) This section details items deducted to arrive at the loss for the six months ended June 30, 2025, including depreciation, amortization, and inventory costs Items Deducted to Arrive at Loss for the Period (For the Six Months Ended June 30) | Item | 2025 (HK$'000) | 2024 (HK$'000) | | :--- | :--- | :--- | | Depreciation of property, plant and equipment | 1,302 | 1,129 | | Depreciation of right-of-use assets | 815 | 700 | | Amortisation of prepayment for distribution rights | 1,741 | 1,423 | | Fair value gains (losses) on financial assets at fair value through profit or loss | 682 | (267) | | Cost of inventories recognised as an expense | 40,940 | 10,306 | [8. Dividends](index=13&type=section&id=8.%20股息) The Board of Directors does not recommend paying any interim dividend for the six months ended June 30, 2025, consistent with the prior period - The Board of Directors does not recommend the payment of any interim dividend for the period (for the six months ended June 30, 2024: nil)[29](index=29&type=chunk) [9. Loss Per Share](index=13&type=section&id=9.%20每股虧損) Basic and diluted loss per share attributable to owners increased to HK$0.45 cents for the six months ended June 30, 2025, with no diluted impact Loss Per Share Calculation (For the Six Months Ended June 30) | Metric | 2025 (HK$'000/share) | 2024 (HK$'000/share) | | :--- | :--- | :--- | | Loss for the period attributable to owners of the Company for the purpose of basic and diluted loss per share | (7,454) | (4,088) | | Weighted average number of ordinary shares for the purpose of basic and diluted loss per share | 1,671,846,657 | 1,671,846,657 | | Basic and diluted loss per share (HK cents) | (0.45) | (0.24) | - The calculation of diluted loss per share for the six months ended June 30, 2025, did not assume the conversion of unexercised share options as their exercise would result in a decrease in loss per share[30](index=30&type=chunk) [10. Property, Plant and Equipment, Right-of-Use Assets and Lease Liabilities](index=13&type=section&id=10.%20物業、廠房及設備、使用權資產及租賃負債) During the period, the Group acquired property, plant and equipment of HK$78 thousand, a decrease from the prior year, with no new lease agreements - During the period, the Group acquired property, plant and equipment of approximately **HK$78 thousand** (2024: approximately HK$567 thousand)[31](index=31&type=chunk) - The Group did not enter into any new lease agreements during the period, thus no new right-of-use assets and lease liabilities were recognized[31](index=31&type=chunk) [11. Equity Instruments at Fair Value Through Other Comprehensive Income / Financial Assets at Fair Value Through Profit or Loss](index=14&type=section&id=11.%20按公平值計入其他全面收益列賬之股本工具%E2%88%95按公平值計入損益列賬之金融資產) As of June 30, 2025, equity instruments at fair value through OCI totaled HK$53,428 thousand, and financial assets at fair value through P&L were HK$44,821 thousand Equity Instruments at Fair Value Through Other Comprehensive Income | Category | June 30, 2025 (HK$'000) | December 31, 2024 (HK$'000) | | :--- | :--- | :--- | | Listed investments: Equity securities listed in Hong Kong | 40,321 | 89,460 | | Unlisted investments: Equity securities | 13,107 | 12,907 | | **Total** | **53,428** | **102,367** | Financial Assets at Fair Value Through Profit or Loss | Category | June 30, 2025 (HK$'000) | December 31, 2024 (HK$'000) | | :--- | :--- | :--- | | Unlisted investments | 44,821 | 44,138 | | **Total** | **44,821** | **44,138** | [12. Inventories](index=14&type=section&id=12.%20存貨) This section pertains to the Group's inventory balances, though specific data is not provided in the outline [13. Trade and Other Receivables](index=15&type=section&id=13.%20貿易及其他應收款項) As of June 30, 2025, total trade and other receivables increased slightly, with a significant portion of trade receivables over 365 days Trade and Other Receivables (As at June 30, 2025) | Item | June 30, 2025 (HK$'000) | December 31, 2024 (HK$'000) | | :--- | :--- | :--- | | Trade receivables (net of allowance for credit losses) | 59,250 | 60,393 | | Other prepayments | 1,942 | 1,600 | | Prepayments to suppliers | 50,441 | 42,547 | | Deposits paid to suppliers (net of allowance for credit losses) | 133,083 | 131,391 | | **Total** | **249,319** | **241,456** | Ageing Analysis of Trade Receivables (As at June 30, 2025) | Ageing | June 30, 2025 (HK$'000) | December 31, 2024 (HK$'000) | | :--- | :--- | :--- | | 0 to 30 days | 22,943 | 24,550 | | 31 to 60 days | 141 | 7,253 | | 61 to 90 days | 1,950 | 1,474 | | 91 to 180 days | 10,371 | 1,274 | | 181 to 365 days | 145 | 4,200 | | Over 365 days | 23,700 | 21,642 | | **Total** | **59,250** | **60,393** | - The Group grants credit periods of **0 to 365 days** to customers and regularly reviews credit limits[33](index=33&type=chunk) [14. Trade and Other Payables](index=16&type=section&id=14.%20貿易及其他應付款項) As of June 30, 2025, total trade and other payables significantly decreased, with an increased proportion of trade payables over 90 days Trade and Other Payables (As at June 30, 2025) | Item | June 30, 2025 (HK$'000) | December 31, 2024 (HK$'000) | | :--- | :--- | :--- | | Trade payables | 12,366 | 21,613 | | Deposits received from customers | 1,305 | 637 | | Contract liabilities | 31 | 30 | | Accruals | 2,240 | 3,887 | | **Total** | **15,942** | **26,167** | Ageing Analysis of Trade Payables (As at June 30, 2025) | Ageing | June 30, 2025 (HK$'000) | December 31, 2024 (HK$'000) | | :--- | :--- | :--- | | 0 to 30 days | 4,177 | 10,286 | | 31 to 60 days | – | 4,114 | | 61 to 90 days | – | 5,431 | | Over 90 days | 8,189 | 1,782 | - The credit period for purchases of goods ranges from **30 to 60 days**, and the Group is required to make prepayments and/or pay deposits to certain suppliers[35](index=35&type=chunk) [15. Share Capital](index=16&type=section&id=15.%20股本) As of June 30, 2025, the Company's authorized share capital was 3,000,000 thousand shares, with 1,671,847 thousand issued and fully paid shares Changes in Share Capital (As at June 30, 2025) | Category | Number of Shares ('000) | Amount (HK$'000) | | :--- | :--- | :--- | | Authorised share capital | 3,000,000 | 150,000 | | Issued and fully paid share capital | 1,671,847 | 83,592 | - There were no changes in the Company's authorised and issued and fully paid share capital from January 1, 2024, to June 30, 2025[36](index=36&type=chunk) [16. Fair Value Measurement of Financial Instruments](index=17&type=section&id=16.%20金融工具之公平值計量) The Group's financial assets are measured at fair value using a hierarchy, with listed securities in Level 1 and unlisted investments primarily in Level 3 Fair Value of Financial Assets Measured at Fair Value on a Recurring Basis (As at June 30, 2025) | Financial Assets | June 30, 2025 (HK$'000) | December 31, 2024 (HK$'000) | Fair Value Hierarchy | Valuation Technique | | :--- | :--- | :--- | :--- | :--- | | Equity instruments at fair value through other comprehensive income listed in Hong Kong | 40,321 | 89,460 | Level 1 | Quoted bid prices in active markets | | Unlisted investments: Equity instruments at fair value through other comprehensive income | 13,107 | 12,907 | Level 3 | Market-based valuation techniques | | Unlisted investments: Financial assets at fair value through profit or loss | 30,336 | 29,874 | Level 3 | Discounted cash flow method | | Unlisted investments: Financial assets at fair value through profit or loss | 14,485 | 14,264 | Level 3 | Adjusted net asset value | - Level 3 fair value measurements involve unobservable inputs such as discount rates, terminal growth rates, and discounts for lack of marketability, whose changes would impact fair value measurements[38](index=38&type=chunk)[40](index=40&type=chunk) - There were no transfers between Level 1 and Level 2, or into or out of Level 3 fair value measurements during the period[41](index=41&type=chunk) [Management Discussion and Analysis](index=19&type=section&id=管理層討論及分析) This section provides management's perspective on the Group's operational and financial performance, outlook, and key developments [Company Overview](index=19&type=section&id=公司概覽) New Ray Medicine International Holding Limited is a pharmaceutical distributor in Hangzhou, China, engaged in product distribution and marketing services across multiple provinces - The Group is principally engaged in the distribution and trading of pharmaceutical and related products and providing marketing and promotion services in China[44](index=44&type=chunk) - The Group's customer network spans various regions in China, including Zhejiang, Jiangsu, Hainan, Hunan, and Guangdong provinces[44](index=44&type=chunk) [Overview](index=19&type=section&id=概覽) For the six months ended June 30, 2025, total revenue increased by 167.4% due to new product launches, but net loss widened to HK$7,454 thousand - Total revenue for the period was approximately **HK$44,701 thousand**, an increase of approximately **167.4%** compared to the same period in 2024[45](index=45&type=chunk) - The increase in revenue was primarily due to the launch of new pharmaceutical products in China by the Group since the second half of 2024[45](index=45&type=chunk) - A net loss of approximately **HK$7,454 thousand** was recorded for the period, with the increased loss mainly attributed to reduced gross profit (due to lower gross margins of new products) and decreased sales volume of key products[45](index=45&type=chunk) [Business Review](index=19&type=section&id=業務回顧) During the period, the Group's revenue primarily stemmed from pharmaceutical product distribution and marketing services, mainly focusing on injectable drugs - The Group's revenue in China is contributed by the distribution and trading of pharmaceutical and related products and the provision of marketing and promotion services[46](index=46&type=chunk) - The main category of pharmaceutical products distributed by the Group is injectable drugs[46](index=46&type=chunk) [Revenue and Segment Information](index=20&type=section&id=收益及分部資料) The Group's revenue is predominantly from pharmaceutical product distribution, which grew by 255.4%, while marketing and promotion services revenue significantly declined Revenue Contribution by Business Segment (For the Six Months Ended June 30) | Business Segment | 2025 (HK$'000) | 2025 (%) | 2024 (HK$'000) | 2024 (%) | | :--- | :--- | :--- | :--- | :--- | | Distribution and trading of pharmaceutical and related products | 43,058 | 96.3 | 12,116 | 72.5 | | Provision of marketing and promotion services | 1,643 | 3.7 | 4,602 | 27.5 | | **Total** | **44,701** | **100.0** | **16,718** | **100.0** | [(1) Distribution and Trading of Pharmaceutical and Related Products](index=20&type=section&id=(1)%20醫藥及相關產品分銷及貿易) Revenue from this segment increased by 255.4% to HK$43,058 thousand, driven by new product launches, partially offset by decreased demand for key products - Revenue from the distribution and trading of pharmaceutical and related products segment was approximately **HK$43,058 thousand**, an increase of approximately **255.4%** compared to the same period in 2024[50](index=50&type=chunk) - The increase in revenue was mainly due to the launch of new products in China by the Group since the second half of 2024, partially offset by decreased demand for a key product (second-generation cephalosporin product (1.0g))[50](index=50&type=chunk) [(2) Provision of Marketing and Promotion Services](index=20&type=section&id=(2)%20提供營銷及推廣服務) Revenue from marketing and promotion services decreased by 64.3% to HK$1,643 thousand, reflecting adjustments after China's 'Two-Invoice System' - Revenue from the provision of marketing and promotion services segment was approximately **HK$1,643 thousand**, a decrease of approximately **64.3%** compared to the same period in 2024[51](index=51&type=chunk) - The Group developed its pharmaceutical product marketing and promotion services business since 2017 due to the implementation of China's 'Two-Invoice System'[51](index=51&type=chunk) [Outlook](index=21&type=section&id=展望) The Group anticipates downward pressure on drug prices due to healthcare reforms and volume-based procurement, focusing on product diversification and sales enhancement - China's healthcare industry faces challenges from volume-based procurement policies, with anticipated downward pressure on drug prices in the future[52](index=52&type=chunk)[54](index=54&type=chunk) - The **ninth round of volume-based procurement** was completed in November 2023, covering **41 drug varieties**, with an average price reduction of approximately **58%** compared to the original tender average price[52](index=52&type=chunk) - The **tenth round of volume-based procurement** was completed in December 2024, covering **385 drug varieties**, with an average price reduction exceeding **60%**[53](index=53&type=chunk) [Continue to Enrich Existing Product Portfolio](index=22&type=section&id=繼續豐富現有產品組合) The Group plans to acquire new product distribution rights and strengthen distribution channels and marketing strategies in H2 2025 for sustainable growth - The Group will seek to acquire distribution rights for new products to enhance its product portfolio[55](index=55&type=chunk) - Looking ahead to the second half of 2025, the Group will continue to enhance its product portfolio, distribution channels, and marketing and promotion strategies[55](index=55&type=chunk) [Continue to Improve and Enhance Sales and Marketing Capabilities](index=22&type=section&id=繼續提高及增強銷售及營銷能力) To enhance competitiveness, the Group will strengthen its local distribution network and sales and marketing capabilities, exploring opportunities to boost distribution - The Group will continue to strengthen its local distribution network and sales and marketing capabilities in the future[56](index=56&type=chunk) - The Group has been exploring various opportunities to enhance its distribution capabilities[56](index=56&type=chunk) [Focus on Our Core Business](index=22&type=section&id=專注我們的核心業務) The Group's long-term strategy focuses on pharmaceutical product distribution and marketing services, reallocating resources and seeking M&A opportunities - The Group intends to focus on its core businesses, namely the distribution and trading of pharmaceutical products and the provision of marketing and promotion services for pharmaceutical products in China[57](index=57&type=chunk) - The Group will continue to seek potential merger and acquisition opportunities to generate higher returns for shareholders[57](index=57&type=chunk) [Financial Review](index=22&type=section&id=財務回顧) This section reviews the Group's financial performance for the six months ended June 30, 2025, covering revenue, cost of sales, gross profit, and net loss [Revenue](index=22&type=section&id=收益) Total revenue for the period increased by 167.4% to HK$44,701 thousand, driven by new product launches, partially offset by decreased demand for key products - Total revenue for the period was approximately **HK$44,701 thousand**, an increase of approximately **167.4%** compared to approximately HK$16,718 thousand for the six months ended June 30, 2024[58](index=58&type=chunk) - The increase in revenue was due to the launch of new products in China by the Group since the second half of 2024, partially offset by decreased demand for key products[58](index=58&type=chunk) [Cost of Sales](index=22&type=section&id=銷售成本) Cost of sales for the period significantly increased by 291.4% to HK$41,065 thousand, primarily due to higher sales of new products - Cost of sales for the period was approximately **HK$41,065 thousand**, an increase of approximately **291.4%** compared to approximately HK$10,492 thousand for the six months ended June 30, 2024[59](index=59&type=chunk) - The increase in cost of sales was mainly due to increased sales of new products during the period[59](index=59&type=chunk) [Gross Profit and Gross Margin](index=23&type=section&id=毛利及毛利率) Gross profit decreased by 41.6% to HK$3,636 thousand, with gross margin falling to 8.13%, due to lower new product margins and reduced key product sales - Gross profit decreased by approximately **41.6%** from approximately HK$6,226 thousand in the same period of 2024 to approximately **HK$3,636 thousand** for the period[60](index=60&type=chunk) - The Group's gross margin for the period was only approximately **8.13%**, a decrease of **29.1 percentage points** compared to the same period in 2024[60](index=60&type=chunk) - The decrease in gross profit and gross margin was mainly due to the new products being in their initial stage with relatively lower gross margins, and decreased sales volume of key products[60](index=60&type=chunk) [Other Income, Gains and Losses](index=23&type=section&id=其他收入、收益及虧損) The Group recorded a net other loss of HK$709 thousand for the period, compared to a gain of HK$735 thousand in the prior year, due to reduced interest and dividend income - Net other loss for the period was approximately **HK$709 thousand** (2024: approximately HK$735 thousand gain)[61](index=61&type=chunk) - The change was mainly due to a decrease in bank interest income of approximately **HK$396 thousand** and a decrease in dividend income from equity instruments at fair value through other comprehensive income of approximately **HK$419 thousand** during the period[61](index=61&type=chunk) [Selling and Distribution Expenses](index=23&type=section&id=銷售及分銷開支) Selling and distribution expenses for the period slightly increased by 2.1% to HK$4,977 thousand compared to the prior year - Selling and distribution expenses for the period were approximately **HK$4,977 thousand**, a slight increase of approximately **2.1%** compared to approximately HK$4,876 thousand for the six months ended June 30, 2024[62](index=62&type=chunk) [Administrative Expenses](index=23&type=section&id=行政開支) Administrative expenses for the period slightly increased by 2.3% to HK$6,003 thousand compared to the prior year - Administrative expenses for the period were approximately **HK$6,003 thousand**, a slight increase of approximately **2.3%** compared to approximately HK$5,867 thousand for the six months ended June 30, 2024[63](index=63&type=chunk) [Income Tax Expense](index=23&type=section&id=所得稅開支) Income tax expense for the period was zero, consistent with the prior year, as the Group had no taxable profits - Income tax expense for the period was **nil** (2024: HK$5 thousand)[64](index=64&type=chunk) - The Group had no taxable profits for which tax provision was made[64](index=64&type=chunk) [Loss for the Period](index=23&type=section&id=期內虧損) Loss for the period increased to HK$7,454 thousand, primarily due to reduced bank interest income and a significant decline in gross profit and gross margin - Loss for the period was approximately **HK$7,454 thousand**, compared to a loss of approximately HK$4,088 thousand for the same period in 2024[65](index=65&type=chunk) - The increased loss was mainly due to decreased bank interest income and a significant reduction in gross profit and gross margin (attributable to lower gross margins of new products and decreased demand for key products)[65](index=65&type=chunk) [Liquidity and Financial Resources](index=24&type=section&id=流動資金及財務資源) The Group maintained a sound liquidity position, primarily funded by internal resources, with HK$54,153 thousand in cash and cash equivalents and a zero gearing ratio - The Group maintained a sound liquidity position during the period, with operations primarily funded by internal resources[67](index=67&type=chunk) Net Cash and Cash Equivalents (As at June 30, 2025) | Metric | June 30, 2025 (HK$'000) | December 31, 2024 (HK$'000) | | :--- | :--- | :--- | | Net cash and cash equivalents | 54,153 | 64,255 | | HKD denominated proportion | 9.0% | 13.6% | | RMB denominated proportion | 91.0% | 86.4% | - As of June 30, 2025, the Group had no bank loans, and its gearing ratio was **zero**[67](index=67&type=chunk) [Contingent Liabilities](index=24&type=section&id=或然負債) As of June 30, 2025, the Group had no significant contingent liabilities - As of June 30, 2025, the Group had no significant contingent liabilities[68](index=68&type=chunk) [Material Investments, Acquisitions and Disposals](index=24&type=section&id=重大投資、重大收購及出售) The Group entered a cooperation agreement to invest HK$16.5 million in a health industrial park project and disposed of its investment in Jiangxi Yimaiyangguang Group for HK$12.8 million [Signing of Cooperation Agreement and Establishment of Target Company](index=24&type=section&id=簽署合作協議及成立目標公司) China New Ray, a subsidiary, entered a cooperation agreement to establish a target company with partners, investing HK$16.5 million for a 20% stake in a health industrial park project - China New Ray, Partner A, and Partner B entered into a cooperation agreement to establish a target company, with China New Ray holding a **20% equity interest**[69](index=69&type=chunk) - China New Ray will inject **HK$16.5 million** (or equivalent RMB), funded by the Group's internal resources[69](index=69&type=chunk) - The target company aims to engage in a project involving the investment and construction of a health industrial park in Shengzhou City, Zhejiang Province, China[70](index=70&type=chunk) [Disposal of Investment in Jiangxi Yimaiyangguang Group](index=25&type=section&id=出售於江西一脈陽光集團之投資) The Group disposed of 801,000 H shares of Jiangxi Yimaiyangguang Group for approximately HK$12.8 million, realizing a gain of HK$0.8 million and increasing liquidity - China New Ray, an indirect wholly-owned subsidiary of the Company, disposed of a total of **801,000 H shares** of Jiangxi Yimaiyangguang Group in the open market for a total consideration of approximately **HK$12.8 million**[74](index=74&type=chunk) - The Group expects to receive gross proceeds of approximately **HK$12.8 million** from the disposal and recognized a gain of approximately **HK$0.8 million**[74](index=74&type=chunk) - The disposal was considered a good opportunity to realize the investment and increase the Group's liquidity, with proceeds intended for general working capital[74](index=74&type=chunk) [Capital Structure](index=25&type=section&id=資本結構) The Company's capital structure remained unchanged during the period, but a post-period share capital reorganization was implemented to adjust share par value - There were no changes in the Company's capital structure during the period[77](index=77&type=chunk) - Subsequent to the period, the Company undertook a share capital reorganization, including share consolidation, capital reduction, and share subdivision[77](index=77&type=chunk) [Share Capital Reorganisation](index=26&type=section&id=股本重組) Effective July 22, 2025, the Company implemented a share capital reorganization involving share consolidation, capital reduction, and share subdivision, resulting in 167,184,665 new shares - The share capital reorganization became effective on **July 22, 2025**, comprising share consolidation, capital reduction, and share subdivision[78](index=78&type=chunk)[79](index=79&type=chunk) - The share consolidation involved consolidating every **ten (10) existing shares** of HK$0.05 par value each into **one (1) consolidated share** of HK$0.50 par value[78](index=78&type=chunk) - The capital reduction reduced the par value of each consolidated share from **HK$0.50 to HK$0.01**, and subdivided the authorized but unissued consolidated shares into **fifty (50) new shares** of HK$0.01 par value each[78](index=78&type=chunk) - Immediately following the effective date of the share capital reorganization, the Company had **167,184,665 new shares** of HK$0.01 par value each in issue[79](index=79&type=chunk) [Pledge of Assets](index=26&type=section&id=資產抵押) As of June 30, 2025, and December 31, 2024, the Group had not pledged any of its assets - As of June 30, 2025, and December 31, 2024, the Group had not pledged any of its assets[80](index=80&type=chunk) [Equity Instruments at Fair Value Through Other Comprehensive Income](index=27&type=section&id=按公平值計入其他全面收益列賬之股本工具) The Group's equity instruments at fair value through OCI include Hong Kong-listed and unlisted equity securities, with fair value losses recognized during the period - The Group's equity instruments at fair value through other comprehensive income primarily comprise equity instruments listed in Hong Kong and unlisted investments[81](index=81&type=chunk) - During the period, fair value losses of approximately **HK$46.9 million** (including fair value losses on Convoy Global Holdings Limited shares) were recognized through other comprehensive income (non-recycling reserve)[84](index=84&type=chunk) [Convoy Global Holdings Limited](index=27&type=section&id=康健國際醫療集團有限公司) As of June 30, 2025, the Group's investment in Convoy Global Holdings Limited was valued at HK$28.0 million, representing 1.74% of its issued share capital, with fair value losses recognized - As of June 30, 2025, the fair value of the Group's investment in shares of Convoy Global Holdings Limited was approximately **HK$28.0 million**[82](index=82&type=chunk) - The Group recognized a fair value loss of approximately **HK$0.8 million** on its investment in Convoy Global Holdings Limited shares during the period[82](index=82&type=chunk) - As of June 30, 2025, the Group held **117,602,000 shares** of Convoy Global Holdings Limited, representing approximately **1.74%** of its total issued share capital[83](index=83&type=chunk) [Other Hong Kong Listed Securities Investments](index=28&type=section&id=其他香港上市證券投資) As of June 30, 2025, other Hong Kong-listed securities investments amounted to HK$12.3 million, with sales generating HK$3.3 million and a fair value gain of HK$1.0 million - As of June 30, 2025, the fair value of the Group's other listed securities investments in Hong Kong (excluding Convoy Global Holdings Limited shares) amounted to approximately **HK$12.3 million**[84](index=84&type=chunk) - During the period, the Group disposed of certain equity securities listed in Hong Kong, generating proceeds of approximately **HK$3.3 million** and a fair value gain of approximately **HK$1.0 million**[84](index=84&type=chunk) [Financial Assets at Fair Value Through Profit or Loss](index=28&type=section&id=按公平值計入損益列賬之金融資產) The Group's financial assets at fair value through P&L primarily include investments in Shengzhou Xinrui Wanma Industrial Co., Ltd. and Shengzhou Xinrui Wanlin Enterprise Management Co., Ltd., both recognizing fair value gains - The Group's financial assets at fair value through profit or loss include investments in Shengzhou Xinrui Wanma Industrial Co., Ltd. and Shengzhou Xinrui Wanlin Enterprise Management Co., Ltd.[85](index=85&type=chunk) [Shengzhou Xinrui Wanma](index=28&type=section&id=嵊州新銳萬馬) As of June 30, 2025, the Group held a 39% equity interest in Shengzhou Xinrui Wanma, with an investment fair value of HK$30.3 million and a recognized fair value gain of HK$0.5 million - As of June 30, 2025, the Group held approximately **39% equity interest** in Shengzhou Xinrui Wanma, with an investment fair value of approximately **HK$30.3 million**[86](index=86&type=chunk) - The Group recognized a fair value gain of approximately **HK$0.5 million** on its investment in Shengzhou Xinrui Wanma during the period[86](index=86&type=chunk) - Shengzhou Xinrui Wanma is constructing and developing a health industrial park, with all Phase I units sold and **31 Phase II units** contracted for sale, totaling approximately **RMB221 million**[87](index=87&type=chunk) [Shengzhou Xinrui Wanlin](index=29&type=section&id=嵊州新銳萬霖) As of June 30, 2025, the Group held a 39% equity interest in Shengzhou Xinrui Wanlin, with an investment fair value of HK$14.5 million and a recognized fair value gain of HK$0.2 million - As of June 30, 2025, the Group held approximately **39% equity interest** in Shengzhou Xinrui Wanlin, with an investment fair value of approximately **HK$14.5 million**[88](index=88&type=chunk) - The Group recognized a fair value gain of approximately **HK$0.2 million** on its investment in Shengzhou Xinrui Wanlin during the period[88](index=88&type=chunk) - Shengzhou Xinrui Wanlin aims to participate in the development of a health food industrial park project located in Shengzhou City, Zhejiang Province, China[88](index=88&type=chunk) [Future Plans for Material Investments](index=29&type=section&id=重大投資的未來計劃) The Group currently has no other future plans for material investments beyond those disclosed in this report - Save as disclosed in this report, the Group currently has no other future plans for material investments[90](index=90&type=chunk) [Other Information](index=30&type=section&id=其他資料) This section covers additional disclosures including employee information, foreign currency risk, share offer proceeds, and corporate governance matters [Employee Information](index=30&type=section&id=僱員資料) As of June 30, 2025, the Group had 30 employees with staff costs of HK$4,127 thousand, and a compensation policy based on position, responsibility, and performance - As of June 30, 2025, the Group had **30 employees** (December 31, 2024: 29 employees)[91](index=91&type=chunk) - Staff costs (including directors' emoluments) for the period were approximately **HK$4,127 thousand** (2024: approximately HK$4,022 thousand)[91](index=91&type=chunk) - The Group's remuneration policy is based on employees' positions, responsibilities, and performance, providing comprehensive compensation and benefits, including a provident fund scheme[91](index=91&type=chunk) [Foreign Currency Risk](index=30&type=section&id=外幣風險) The Group's primary business is RMB-denominated in China, but it holds HKD and USD bank balances, exposing it to foreign currency risk, though no hedging policy is adopted - The Group conducts business in China, with most transactions denominated in Renminbi, but holds Hong Kong Dollar and US Dollar bank balances, exposing it to foreign currency risk[92](index=92&type=chunk) - The Directors believe that the potential impact of exchange rate fluctuations on the Group's profit or loss is not material, thus no foreign currency hedging policy has been adopted[92](index=92&type=chunk) [Net Proceeds from Rights Issue](index=30&type=section&id=供股所得款項淨額) The Company completed a rights issue in 2017, raising HK$330.0 million, with the remaining HK$22.3 million re-designated for general working capital and fully utilized during the period - The Company completed a rights issue on **March 6, 2017**, with net proceeds of approximately **HK$330.0 million**[93](index=93&type=chunk) - As of December 31, 2024, the remaining unutilized net proceeds from the rights issue (approximately **HK$22.3 million**) were re-designated for general working capital[93](index=93&type=chunk) - During the period, the Company fully utilized the remaining portion of the net proceeds for general working capital[93](index=93&type=chunk) [Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures](index=31&type=section&id=董事及最高行政人員於股份、相關股份及債權證的權益及淡倉) As of June 30, 2025, executive directors Ms. Wang Qiuqin, Mr. Chu Xueping, and Ms. Zhou Wan held long positions in the Company's shares or underlying shares, with Mr. Chu holding significant interests Directors' and Chief Executive's Interests in Shares (As at June 30, 2025) | Name of Director/Chief Executive | Capacity | Number of Relevant Shares | Position | Approximate Percentage of Total Issued Shares | | :--- | :--- | :--- | :--- | :--- | | Ms. Wang Qiuqin | Beneficial owner | 16,600,000 | Long position | 0.99% | | Mr. Chu Xueping | Beneficial owner | 443,272,000 | Long position | 26.51% | | Ms. Zhou Wan | Beneficial owner | 15,000,000 | Long position | 0.90% | - Mr. Chu Xueping's interests include beneficially owned share options and a share interest of **426,672,000 shares** held through his controlled corporation, Eagle Amber Holdings Limited[94](index=94&type=chunk) - The exercise period for all directors' share options is from **June 14, 2022, to June 13, 2027**, with an exercise price of **HK$0.287 per share**[94](index=94&type=chunk) [Substantial Shareholders' Interests and Short Positions in Shares and Underlying Shares](index=32&type=section&id=主要股東於股份及相關股份的權益及淡倉) As of June 30, 2025, Eagle Amber Holdings Limited held 25.52% of the Company's shares, with Mr. Chu Xueping and Mr. Dai Xiaosong each beneficially owning 50%, and Mr. Zhou Ling and Ms. Yang Fang collectively holding 9.65% Substantial Shareholders' Interests in Shares (As at June 30, 2025) | Name of Shareholder | Capacity | Number of Ordinary Shares | Position | Approximate Percentage of Total Issued Shares | | :--- | :--- | :--- | :--- | :--- | | Eagle Amber Holdings Limited | Beneficial owner | 426,672,000 | Long position | 25.52% | | Dai Xiaosong | Interest in controlled corporation | 426,672,000 | Long position | 25.52% | | Zhou Ling | Beneficial owner and spouse's interest | 161,400,000 | Long position | 9.65% | | Yang Fang | Beneficial owner and spouse's interest | 161,400,000 | Long position | 9.65% | - Eagle Amber Holdings Limited is beneficially owned **50.0%** by Mr. Chu Xueping and Mr. Dai Xiaosong respectively, thus both are deemed to have an interest in the shares held by it[98](index=98&type=chunk) - Mr. Zhou Ling and Ms. Yang Fang are spouses, and under the Securities and Futures Ordinance, they are deemed to have an interest in the shares held by each other[99](index=99&type=chunk) [Share Option Scheme](index=33&type=section&id=購股權計劃) The Company's share option scheme, effective October 25, 2013, expired in October 2023, with no options granted, exercised, cancelled, or lapsed during the period, but 128,200,000 options remain unexercised - The Company's share option scheme became effective on **October 25, 2013**, with a ten-year validity period, and expired in **October 2023**[100](index=100&type=chunk)[101](index=101&type=chunk) - No share options were granted, exercised, cancelled, or lapsed under the scheme during the period[100](index=100&type=chunk) Number of Outstanding Share Options (As at June 30, 2025) | Category of Participants | Outstanding as at June 30, 2025 | Exercise Period | Exercise Price per Share (HK$) | | :--- | :--- | :--- | :--- | | Directors (Wang Qiuqin, Chu Xueping, Zhou Wan) | 48,200,000 | June 14, 2022 to June 13, 2027 | 0.287 | | Employees | 80,000,000 | June 14, 2022 to June 13, 2027 | 0.287 | | **Total** | **128,200,000** | | **0.287** | [Directors' Rights to Acquire Shares or Debentures of the Company](index=34&type=section&id=董事購買本公司股份或債權證的權利) No arrangements were made during the period for directors or their families to acquire shares or debentures of the Company or other corporations, beyond disclosed interests and share option schemes - Save for the disclosed directors' interests and share option scheme, neither the Company nor any of its subsidiaries entered into any arrangements during the period enabling directors or their families to acquire benefits by purchasing shares or debentures of the Company or any other corporation[102](index=102&type=chunk) [Compliance with Corporate Governance Code](index=34&type=section&id=遵守企業管治守則) The Company complied with the Corporate Governance Code during the period, though the combined roles of Chairman and CEO (Ms. Wang Qiuqin) represent a deviation, which the Board reviews periodically - The Company has adopted and complied with the Corporate Governance Code set out in Appendix C1 to the Listing Rules during the period[103](index=103&type=chunk)[104](index=104&type=chunk) - Ms. Wang Qiuqin serves concurrently as Executive Director, Chairman of the Board, and Chief Executive Officer, which constitutes a deviation from Code Provision C.2.1 of the Corporate Governance Code (requiring separation of Chairman and Chief Executive Officer roles)[103](index=103&type=chunk) - The Board believes that the balance of power and authority under this arrangement is adequate and will review the structure from time to time, potentially seeking a suitable candidate for the Chairman position[103](index=103&type=chunk) [Standard Code for Securities Transactions by Directors](index=35&type=section&id=董事進行證券交易的標準守則) The Company adopted the Standard Code for Securities Transactions by Directors, and all directors confirmed compliance during the period - The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules as its code of conduct for directors' securities transactions[105](index=105&type=chunk) - Following specific enquiries with all Directors, all Directors confirmed their compliance with the required standards set out in the Model Code during the period[105](index=105&type=chunk) [Purchase, Sale or Redemption of the Company's Listed Securities](index=35&type=section&id=購入、出售或贖回本公司上市證券) Neither the Company nor its subsidiaries purchased, sold, or redeemed any of the Company's listed securities during the period - Neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed securities during the period[106](index=106&type=chunk) [Litigation](index=35&type=section&id=訴訟) The Company is involved in an ongoing appeal by the SFC regarding a petition alleging misconduct by two former directors from 2015 to 2018, despite a court judgment awarding costs to the Company - The Company was served with a petition filed by the SFC with the High Court of Hong Kong on **November 17, 2020**, pursuant to Section 214 of the Securities and Futures Ordinance[107](index=107&type=chunk) - The petition alleged unlawful or other misconduct by two former directors (Mr. Zhou Ling and Mr. Dai Haidong) between **2015 and 2018**, including breaches of directors' duties, secret profits, and fictitious transactions[107](index=107&type=chunk) - The Court delivered its judgment on **September 13, 2024**, awarding costs to the Company, but the SFC filed a notice of appeal on **October 10, 2024**, and the appeal is ongoing[109](index=109&type=chunk)[111](index=111&type=chunk) [Adoption of New Bye-laws](index=37&type=section&id=採納新細則) Shareholders adopted new bye-laws on June 18, 2025, to comply with updated Listing Rules, allowing for electronic meetings and providing flexibility for treasury shares - The Board recommended amending the Company's bye-laws to comply with the latest regulatory requirements of the Listing Rules regarding the expanded paperless listing regime and mandatory electronic dissemination of corporate communications by listed issuers[113](index=113&type=chunk) - The new bye-laws explicitly permit the Company to convene and hold electronic meetings and/or hybrid meetings in addition to physical meetings[113](index=113&type=chunk) - The new bye-laws were adopted by shareholders of the Company via a special resolution at the annual general meeting held on **June 18, 2025**[113](index=113&type=chunk) [Audit Committee](index=37&type=section&id=審核委員會) The Audit Committee, comprising three independent non-executive directors, reviews financial statements, accounts, and results, and oversees financial reporting, risk management, and internal controls - The primary responsibilities of the Audit Committee include reviewing the Company's financial statements, accounts, and interim and annual results, and providing advice and recommendations to the Board thereon[114](index=114&type=chunk) - The Audit Committee comprises three independent non-executive directors: Ms. Li Qianming (Chairperson), Mr. Leung Chi Kin, and Mr. Sze Lai Shan[114](index=114&type=chunk) - The Audit Committee has reviewed the Group's unaudited condensed consolidated financial statements for the period and this report[115](index=115&type=chunk)

FF301 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06108 | 說明 | 新銳醫藥 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | HKD | | 0.01 HKD | | 150,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.01 HKD | | 150,000,000 | 本月底法定/註冊股本總額： HKD 150,000,000 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 新銳 ...

期内收益增加乃由于集团自2024年下半年起于中国推出新产品及部分被该产品于期内的需求下跌抵销， 其原因为中国内地多个地区进一步加强采用抗菌药物分级分类管理政策，带来持续不利影响。 智通财经APP讯，新锐医药(06108)发布2025年中期业绩，收益4470.1万港元，同比增长167.4%;净亏损 745.4万港元，同比扩大82.3%;每股基本亏损0.45港仙。 ...

期内收益增加乃由于集团自2024年下半年起于中国推出新产品及部分被该产品于期内的需求下跌抵销， 其原因为中国内地多个地区进一步加强采用抗菌药物分级分类管理政策，带来持续不利影响。 新锐医药(06108)发布2025年中期业绩，收益4470.1万港元，同比增长167.4%;净亏损745.4万港元，同比 扩大82.3%;每股基本亏损0.45港仙。 ...

格隆汇8月27日丨新锐医药(06108.HK)公告，截至2025年6月30日止六个月，集团录得收益约44,701,000 港元，同比增加约167.4%。公司拥有人应占亏损净额约为7,454,000港元，较2024年同期的公司拥有人 应占亏损净额约4,088,000港元增加约82.3%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 New Ray Medicine International Holding Limited （於百慕達註冊成立之有限公司） （股份代號：6108） 截至二零二五年六月三十日止六個月之 中期業績公告 財務概要 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月： 於 二 零 二 五 年 六 月 三 十 日： • 本 集 團 於 二 零 二 五 年 六 月 三 十 日 的 資 產 負 債 比 率（界 定 為 銀 行 及 其 他 借 款 總 額 除 以 總 權 益）為 零（二 零 二 四 年 十 二 月 三 十 一 日：零）。 – 1 – • 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月，本 集 團 錄 得 收 益 約44,701,000港 元，較 二 零 二 ...

格隆汇8月15日丨 新锐医药(06108.HK)公布，公司将于2025年8月27日召开董事会会议，以（其中包 括）审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及审议派发中期股息的建议 （如有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 香 港，二 零 二 五 年 八 月 十 五 日 於 本 公 告 日 期，執 行 董 事 為 王 秋 勤 女 士、褚 雪 平 先 生 及 周 灣 女 士；及 獨 立 非 執 行 董 事 為 梁 志 堅 先 生、李 倩 明 女 士 及 施 禮 賢 先 生。 新 銳 醫 藥 國 際 控 股 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 將 會 於 二 零 二 五 年 八 月 二 十 七 日（星 期 三）舉 行 會 議，以（其 中 包 括）考 慮 及 批准本公司及其附屬公司截至二零二五年六月三十日止六個月的未經審核中 期 業 績 及 其 刊 發，以 及 考 慮 是 否 派 付 股 息（如 有）。 代表董事會 新銳醫藥國際控股有限公司 主 席、行 政 ...